MASTER DAPT - Study news

 

First patient enrolled

Emmen, The Netherlands, 4th of April 2017 – Dr Gillian Jessurun from Treant Zorggroep, Scheper Hospital has enrolled the first patient in the investigator initiated MASTER DAPT (MAnagement of patients post bioresorbable polymer STEnt implantation with an abbreviated DAPT regimen) study, effectively launching the ambitious global investigation.

Dr Gillian Jessurun, proud of enrolling the first patient, commented: “Having the privilege of enrolling the study’s first patient reflects our team and Treant Zorggroep, Scheper Hospital’s commitment to research.”

Dr Peter Smits, Head of Intervention Cardiology, Maasstad Hospital and study Co-Principal Investigator said: “This new trial is an important step towards gathering robust evidence to define the safest DAPT regimen in this sizable proportion of patients treated in contemporary PCI practice. It’s great that The Netherlands is the first of 34 countries worldwide to contribute to this important scientific work.”

Co-Principal Investigator Dr Marco Valgimigli, Prof of Cardiology and Director of Clinical Research, Inselspital Universitätsspital Bern, Switzerland, said: “We’ve been working on this study for a long time, so it’s a very rewarding moment to see it get underway with our first patient enrolled. We have an ambitious target but I am optimistic that with the support of many highly motivated centres and investigators across the globe we will get there.”